Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. has announced final approval for a pioneering Phase 2B clinical trial on MB22001, a take-home microdose form of LSD for treating Major Depressive Disorder (MDD). The trial aims to build on the success of a previous study where over half the participants achieved complete remission. This groundbreaking research could offer new hope to the millions affected by MDD worldwide, as current treatments often have limited effectiveness.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
